Noxxon was awarded a $1.6M (1M euro) research grant from Germany’s Federal Ministry of Education and Research. The funding was offered under the BioChancePlus initiative, a program that supports innovative research in biotechnology companies.
The grant will be applied to strengthening and broadening the firm’s Spiegelmer® drug discovery platform to identify innovative medicines.
A Spiegelmer® is a mirror-image oligonucleotide that can bind to a pharmacologically relevant target molecule in a manner conceptually similar to an antibody that recognizes an antigen, according to the company. The mirror image configuration of the oligonucleotide reportedly confers stability in all biological environments, as naturally occurring nucleases cannot degrade Spiegelmers.